AliveDx Suisse S.A. and Lavichem Joint Stock Company have signed a distribution agreement, which will enable Lavichem to distribute the MosaiQ® solution in North Vietnam. The distribution agreement takes effect immediately.
AliveDx is committed to broadening its reach and presence across different regions, aiming to generate both clinical and economical value for clinicians, helping them to shorten the time to diagnosis. This new partnership with a significant player in North Vietnam underscores the company’s dedication to supporting the healthcare sector and enhancing patient care.
The MosaiQ platform simplifies workflows and creates efficiencies thanks to its multiplexing microarray assay technology. This streamlined and efficient approach offers faster and more cost-effective solutions to healthcare providers and patients alike.
“We are thrilled to unveil our partnership with Lavichem. We are eager to start our collaboration, which aims to provide support to patients and the healthcare community in North Vietnam,” said Manuel O. Méndez, AliveDx’s CEO.
Lavichem was established in 2010 and is based in Hanoi, Vietnam. The company is a key microbiology manufacturer in Vietnam. It is entering the in-vitro diagnostic business and is now further expanding into the Core Lab diagnostic segment.
“We are honored to collaborate with AliveDx. With the MosaiQ solution, we will bring innovative technologies to the healthcare sector, ultimately benefiting patients. Our forthcoming success will be bolstered by our strong partnership with AliveDx. We look forward to a lasting collaboration with AliveDx, given our shared vision and development strategies,” said Miss Huyen, owner of the company.
To learn more, please visit the Lavichem website.
